Logo
Whalesbook
HomeNewsCorporate NewsPremiumStocks
HomeNewsCorporate NewsPremiumStocks

AstraZeneca Pharma India Ltd

₹ 8,272-0.18%
16 Jan 4:01 p.m. – close price
🔗astrazenecaindia.com•BSE: 506820•NSE: ASTRAZEN
Market Cap₹ 20,672 Cr.
Current Price₹ 8,272
High / Low₹ 10,691
Stock P/E89.4
Book Value₹ 320
Dividend Yield0.39 %
ROCE33.4 %
ROE23.6 %
Face Value₹ 2.00
Sales₹ 2,006 Cr.
OPM15.9 %
Mar Cap₹ 20,672 Cr.

ABOUT

AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.[1]

KEY POINTS

Part of AstraZeneca UK plcThe company is promoted by AstraZeneca plc, a multinational pharmaceutical and biotechnology company headquartered in England. It has a diverse portfolio in various disease areas and has been successful in developing and manufacturing the Oxford-AstraZeneca COVID-19 vaccine. AstraZeneca Pharmaceuticals AB holds 75% of the company's shareholding.[1][2]

Also present in buckets:
Aggressive Growth TriggersExcellent ResultsRevenue GuidanceCapacity Expansion And ProductsJv Partnerships AcquisitionsCredit Rating UpdatesRed Flags And Poor Performance

Peer Comparision

S.No.NameCurrent Price (Rs.)Price to EarningMarket Capitalization (Rs.Cr.)Dividend yield (%)Net Profit latest quarter (Rs.Cr.)YOY Quarterly profit growth (%)Sales latest quarter (Rs.Cr.)YOY Quarterly sales growth (%)Return on capital employed (%)Sales (Rs.Cr.)OPM (%)Profit after tax (Rs.Cr.)Profit after tax latest quarter (Rs.Cr.)Price to book valueReturn on assets (%)Debt to equity
1.Sun Pharma.Inds.1669.2034.70400532.320.963124.952.5614478.318.9320.2154964.0130.1211543.963117.955.1512.970.07
2.Divi's Lab.6233.9566.59165459.250.48689.0035.102715.0016.1220.4410029.0032.372485.00689.0010.7413.530.01
3.Torrent Pharma.4018.7562.76135973.700.80591.0032.493302.0014.3027.0512248.0032.602166.53600.1716.1013.260.33
4.Cipla1397.9520.76112914.510.931353.373.737589.447.6422.7228349.5725.405441.141351.173.4314.720.01
5.Lupin2174.2022.9799357.920.551484.8373.347047.5124.2321.3024750.6927.254324.631477.925.0612.410.32
6.Dr Reddy's Labs1179.3017.0598432.100.681336.807.288828.309.8322.6934310.0024.645772.201347.102.7312.950.16
7.Mankind Pharma2173.5551.3389745.240.05520.18-22.003697.1620.7715.9813545.6724.121748.55511.515.878.890.55
8.Astrazeneca Phar8272.0089.4320671.760.3954.2251.26559.0937.0333.402006.1715.93231.1658.1325.8913.490.04
–Median: 149 Co.390.630.031766.00.1113.4911.71161.7610.5814.89591.7315.9345.2613.963.138.560.22

Quarterly Results

Standalone figures in ₹ crores

Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales
236250285295311306383388408440480526559
Expenses
195213225228258291334349355363394445484
Operating Profit
41376067531549385377868175
Other Income
77-32825109-498-2610111
Profit before tax
44392371732054-155142787573
Tax %
26%26%26%25%29%23%27%-22%25%27%26%25%26%
Net Profit
33291754521639-123831585654
EPS in Rs
13.0211.726.9121.5420.956.3215.79-4.7215.3712.3423.3022.3321.69

Profit & Loss

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales
4745175645445717288328148061,0031,2961,7162,006
Expenses
4875285475065256577116787198381,1111,4621,687
Operating Profit
-13-111637467112113586165184254320
Other Income
2367141216131315-1451-56-3
Interest
0000001111112
Depreciation
10151716151519201716154046
Profit before tax
0-21636447311412783134220156268
Net Profit
-1-21520265472936299162116199
EPS in Rs
-0.20-8.342.108.0210.3621.7828.8837.3224.6439.7264.6046.3079.66
Dividend Payout %
0%0%0%0%0%0%3%5%41%40%37%69%–

Compounded Sales Growth

10 Years:13%
5 Years:16%
3 Years:29%
TTM:35%

Compounded Profit Growth

10 Years:26%
5 Years:19%
3 Years:43%
TTM:80%

Stock Price CAGR

10 Years:22%
5 Years:14%
3 Years:34%
1 Year:22%

Return on Equity

10 Years:19%
5 Years:21%
3 Years:23%
Last Year:24%

Balance Sheet

Standalone figures in ₹ crores

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
5555555555555
Reserves
167146151218242296359451506584707765794
Borrowings
00000012129753635
Other Liabilities
244261247193214261330306337389362712781
Total Liabilities
4164124034154615627067758579851,0781,5181,615
Fixed Assets
941019787757572817469676440
Gross Block
169.75191.44203.76102.57105.85119.83132.84159.78168.83179.12187.13217.61–
Accumulated Depreciation
75.5390.46106.4015.7330.3945.0061.3178.8294.34110.26120.45153.37–
CWIP
912654724421000
Investments
0000000000000
Other Assets
3122982993243824806116907809151,0111,4541,575
Total Assets
4164124034154615627067758579851,0781,5181,615

Cash Flows

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity
-1-46573895587105101582865
Cash from Investing Activity
-15-19-40-94-1711735182231
Cash from Financing Activity
860-1000-6-9-9-24-44-66
Net Cash Flow
71-645338-159-902699652531

Ratios

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days
413054293540373839394339
Inventory Days
210157141121229186197198164193140208
Days Payable
241203174184257266251221220231121173
Cash Conversion Cycle
10-1621-347-39-1715-1716274
Working Capital Days
-45-15-28-36-8-14-16-17-34-182022
ROCE %
-12%-13%4%15%19%27%34%30%16%31%31%33%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Promoters
75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%
FIIs
2.61%2.70%2.68%2.69%2.66%2.73%2.79%2.90%2.92%2.89%3.03%2.74%
DIIs
1.42%1.41%1.91%2.42%2.76%3.77%4.99%5.08%5.21%4.65%4.55%5.26%
Public
20.97%20.88%20.40%19.89%19.57%18.50%17.21%17.02%16.85%17.45%17.41%17.00%

* The classifications might have changed from Sep'2022 onwards.ℹ️

BSE Announcements AI Summary

Direct from BSE filings, auto-summarised

AstraZeneca Pharma India seeks member approval via postal ballot to shift registered office to Maharashtra

10th April 2026, 10:53 pm

AstraZeneca Pharma India Announces Senior Management Appointments

1st April 2026, 1:12 am

AstraZeneca Pharma India Shareholders Approve Material Related Party Transactions with UK and Sweden Entities

31st March 2026, 9:28 pm

AstraZeneca Pharma India Receives CDSCO Approval for New Liver Cancer Indication

17th March 2026, 8:35 pm

AstraZeneca Pharma India Files SEBI Compliance Certificate for February 2026

13th March 2026, 10:36 pm

Published by Other Websites

External media mentions & references

Geopolitics Jolt Indian Markets: Sensex Plunges 700 Points

13th April 2026, 4:03 pm

Indian Firms Secure Mega Deals: Infra, Pharma, Chemicals See Major Wins

13th April 2026, 7:42 am

Infra Wins, Pharma Launches Drive Monday Stock Watch: L&T, Apollo, NTPC in Focus

13th April 2026, 7:21 am

M&M Stake Sale, L&T Acquisition, Swiggy Exit: Stocks in Focus April 13

13th April 2026, 7:07 am

AstraZeneca India Expands Cancer Drug Use, Stock Gains on Approval

10th April 2026, 6:26 pm

News Articles

Editorial & research coverage

AstraZeneca India Secures First Perioperative Immunotherapy Approval for Gastric Cancer
AstraZeneca India Secures First Perioperative Immunotherapy Approval for Gastric Cancer

4th February 2026, 3:59 pm

AstraZeneca India moves Gastric Cancer Immunotherapy Earlier
AstraZeneca India moves Gastric Cancer Immunotherapy Earlier

4th February 2026, 3:56 pm

India Budget 2026: Drug Duty Cuts Offer Targeted Relief
India Budget 2026: Drug Duty Cuts Offer Targeted Relief

3rd February 2026, 11:08 am

AstraZeneca India Gains CDSCO Approval for Gastric Cancer Drug
AstraZeneca India Gains CDSCO Approval for Gastric Cancer Drug

31st January 2026, 5:14 pm

India Welcomes New Hope: AstraZeneca Pharma's Advanced Breast Cancer Drug Datverzo Secures Crucial CDSCO Approval!
India Welcomes New Hope: AstraZeneca Pharma's Advanced Breast Cancer Drug Datverzo Secures Crucial CDSCO Approval!

17th December 2025, 11:09 pm

Documents

Announcements

Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Appointment Of Senior Management Personnel

9 Jan - AstraZeneca India appoints Aditi Mehta (Director–Oncology) and Nitin Bindal (Director–Institutional), effective Jan 12, 2026.

Intimation Under Regulation 30 Of SEBI (LODR) Regulation, 2015

17 Dec - AstraZeneca received CDSCO permission to import/sell Datverzo (Datopotamab Deruxtecan) for HR+/HER2- metastatic breast cancer.

Closure of Trading Window
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

8 Dec 2025 - RTA certificate (Dec 2, 2025) confirms AstraZeneca Pharma India compliance with SEBI Regulation 74(5).

Determination Of Materiality - Details Of Key Managerial Personnel

8 Dec 2025 - Provides KMP contact details (MD Praveen Rao; CFO Bhavana Agrawal) for materiality determination, dated Dec 8, 2025.

Annual Reports

Financial Year 2025

(from bse)

Financial Year 2024

(from bse)

Financial Year 2023

(from bse)

Financial Year 2022

(from bse)

Financial Year 2021

(from bse)

Financial Year 2020

(from bse)

Financial Year 2019

(from bse)

Financial Year 2018

(from bse)

Financial Year 2017

(from bse)

Financial Year 2016

(from bse)

Financial Year 2015

(from bse)

Financial Year 2014

(from bse)

Financial Year 2013

(from bse)

Financial Year 2013

(from nse)

Financial Year 2012

(from bse)

Credit Ratings

No credit ratings.

Concalls

Aug 2025

Transcript

Aug 2024

TranscriptPPT

Aug 2023

TranscriptPPT

Aug 2022

TranscriptPPT

Aug 2021

TranscriptPPT

Sep 2020

Transcript

Aug 2020

TranscriptPPT

Jun 2020

Transcript

Dec 2019

Transcript

Jul 2019

Transcript

Sep 2018

PPT

Stock Analysis

Description

  1. AstraZeneca Pharma India Limited is engaged in the manufacture, distribution, and marketing of pharmaceutical products, part of the global AstraZeneca group.

Key Growth Triggers

  1. Currently no data available for Key Growth Triggers.

Order Book

  1. Currently no data available for Order Book.

Key Red Flags

  1. Currently no data available for Key Red Flags.

Key Dates To Watch

  1. January 21, 2026: Scheduled interaction with analysts and investors.

Corporate Announcements

10th Apr 26
Impact Rating: 6
AstraZeneca Pharma India members will vote via e-voting from April 12 to May 11, 2026, on shifting the registered office to Maharashtra, requiring a Special Resolution and MOA amendment. Central Government approval is also needed.
31st Mar 26
Impact Rating: 7
AstraZeneca Pharma India has approved the appointment of Dr. Shashank Srinivasan as Medical Director – Oncology Business Unit and the promotion of Mr. Venkat Natarajan to Director – Market Access Business Unit. Both changes are effective April 1, 2026.
31st Mar 26
Impact Rating: 9
AstraZeneca Pharma India announced that its shareholders approved material related party transactions with AstraZeneca UK and AstraZeneca AB (Sweden) through a postal ballot. Both resolutions passed with a significant majority.
17th Mar 26
Impact Rating: 7
AstraZeneca Pharma India announced CDSCO permission to import Imfinzi for an additional indication, specifically for unresectable hepatocellular carcinoma patients, marking a significant market access step.
13th Mar 26
Impact Rating: 3
AstraZeneca Pharma India Limited has informed exchanges about a compliance certificate from its RTA, Integrated Registry Management Services Private Limited, confirming adherence to SEBI Depositories and Participants Regulations for February 2026.